Interim Condensed Consolidated Financial Statements of

GOLDEN LEAF HOLDINGS LTD.

For the three and six months ended June 30, 2018 (Unaudited)

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018 and 2017

Notice of Refiling of Condensed Interim Financial Statementsi
Notice of No Auditor Review of Condensed Interim Financial Statementsi
Interim Condensed Consolidated Statement of Financial Position (Unaudited) 1
Interim Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)2
Interim Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited)
Interim Condensed Consolidated Statements of Cash Flows (Unaudited)4
Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

Notice of Refiling of Condensed Interim Financial Statements

Golden Leaf Holdings LTD ("the Company") is refiling its Interim Condensed Consolidated Financial Statements (Unaudited) for the three and six months ended June 30, 2018 to correct its Interim Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) on page 3 to include comparative financial information for the corresponding interim period in the immediately preceding financial year for the six month ended June 30, 2017, as required by National Instrument 51-102, *Continuous Disclosure Obligations*. No other changes have been made to the document filed on August 29, 2018.

Notice of No Auditor Review of Condensed Interim Financial Statements

In accordance with National Instrument 51-102, the Company discloses that its external auditors have not reviewed the accompanying condensed interim financial statements of Golden Leaf Holdings Ltd. as of June 30, 2018 and the notes to condensed interim financial statements.

Interim Condensed Consolidated Statement of Financial Position (Unaudited) As at June 30, 2018 and December 31, 2017 (Expressed in U.S. dollars)

		J	une 30, 2018	Dec	ember 31, 2017
ASSETS					
CURRENT					
Cash		\$	15,702,963	\$	6,009,447
Accounts receivable	Note 6	Ŷ	270,919	Ŧ	377,746
Other receivables			136,234		-
Income tax recoverable			748,200		432,000
Sales tax recoverable			549,449		442,832
Biological assets	Note 7		402,675		90,627
Inventory	Note 7		4,059,927		3,623,255
Prepaid expenses and deposits			720,415		348,176
Assets held for sale			35,274		305,274
Total current assets		\$	22,626,056	\$	11,629,357
Property, plant and equipment	Note 8		6,071,676		5,956,910
Intangible assets	Note 9		26,075,826		26,227,116
Goodw ill			31,971,398		31,971,398
Total assets		\$	86,744,956	\$	75,784,781
LIABILITIES current					
Accounts payable and accrued liabilities		\$	1,127,110	\$	2,867,735
Interest payable			1,594		48,524
Current portion of long-term debt	Note 11		40,371		131,610
Current portion of convertible debentures					
carried at fair value	Note 10		-		271,245
Derivative liability			92,178		61,044
Total current liabilities		\$	1,261,253	\$	3,380,158
Long term debt	Note 11		64,455		80,381
Note payable	Note 10		313,816		389,916
Convertible debentures carried at fair value	Note 10		12,016,126		30,360,225
Consideration payable			9,527,350		9,527,350
Warrant liability	Note 12		4,406,297		14,300,616
Total liabilities		\$	27,589,297	\$	58,038,646
SHAREHOLDERS' EQUI	τv		· · · · ·		· ·
	Note 13	\$	138,002,232	\$	108,552,681

Share capital	Note 13	\$ 138,002,232	\$ 108,552,681
Warrant reserve	Note 14	4,078,120	5,083,561
Share option reserve	Note 15	2,100,540	1,087,640
Contributed surplus		59,940	59,940
Accumulated other comprehensive loss		(43,435)	9,828
Deficit		(85,041,738)	(97,047,515)
Total shareholders' equity		\$ 59,155,659	\$ 17,746,135
Total liabilities and shareholders' equity		\$ 86,744,956	\$ 75,784,781

Going Concern (Note 2)

Commitments (Note 16)

Segmented Information (Note 21)

Subsequent events (Note 23)

See accompanying notes to consolidated financial statements.

Interim Condensed Consolidated Statement of Operations and Comprehensive Gain (Loss) (Unaudited) For the three and six months ended June 30, 2018 and 2017 (Expressed in U.S. dollars)

		F	For the three mo	onths er	ided June 30,		For the six month	s ende	ed June 30,
			2018		2017		2018		2017
Revenues									
Product sales		\$	3.671.738	\$	2,089,393	\$	6,854,727	\$	4,348,487
Consulting revenue		Ŷ	9,898	Ŷ	_,000,000	Ŷ	27,176	Ŧ	-
Total Revenue		\$	3,681,636	\$	2,089,393	\$	6,881,903	\$	4,348,487
Inventory expansed to east of a log			2 020 705		4 520 040		5 754 500		2 202 000
Inventory expensed to cost of sales			3,029,795		1,530,212		5,754,508		3,368,899
Production costs			113,753		157,057		411,227		339,065
Gross margin before the undernoted			538,088		402,124		716,168		640,523
Fair value changes in biological assets included									
in inventory sold and other inventory charges			10,518		-		129,648		-
Gain on changes in fair value of biological assets	Note 7		(412,360)			_	(706,257)	-	-
Gross profit		\$	939,930	\$	402,124	\$	1,292,777	\$	640,523
Expenses									
General and administration			3,270,258		2,058,257		6,066,052		3,656,530
Share based compensation	Note 15		567,969		215,221		1,643,421		376,569
Professional fees paid with equity instruments			-		113,071		-		167,491
Sales and marketing			440,751		287,289		824,052		566,212
Depreciation and amortization	Note 8, 9		358,516		71,128		703,795		133,303
Total expenses		\$	4,637,494	\$	2,744,966	\$	9,237,320	\$	4,900,105
Loss before undernoted items		\$	(3,697,564)	\$	(2,342,842)	\$	(7,944,543)	\$	(4,259,582)
Interest expense			266,317		312,411		915,575		857,432
Transaction costs			-		-		471,900		-
Loss on disposal of assets			5,000		294,200		5,000		294,200
Impairment of financing lease receivable			-		27,422		-		54,844
Other loss			36,723		161,903		(122,403)		162,828
Gain on change in fair value of warrant liability	Note 12		(4,415,480)		(82,694)		(10,627,702)		(238,379)
Gain on change in fair value of liabilities	Note 10		(2,841,987)		(1,541,097)		(9,970,603)		(1,585,790)
Gain (loss) before income taxes		\$	3,251,863	\$	(1,514,987)	\$	11,383,690	\$	(3,804,717)
Current income tax expense		Ψ	8,434	Ψ	200,000	Ψ	8,434	Ψ	200,000
Net Gain (Loss)		\$	3,243,429	\$	(1,714,987)	\$	11,375,256	\$	(4,004,717)
Other comprehensive loss		Ψ	0,2.0,120	Ψ	(.,. 1,007)	*	,0.0,200	Ψ	(.,
		\$	34,146			¢	53,263	\$	
Cumulative translation adjustment		Φ	34,140		-	\$	53,203	Φ	-
Comprehensive Gain (Loss)		\$	3,209,283	\$	(1,714,987)	\$	11,321,993	\$	(4,004,717)
Basic and diluted gain (loss) per share		\$	0.01	\$	(0.01)	\$	0.02		(0.03)
Weighted average number of common shares outsta	anding		575,776,971		143,604,908		555,451,438		131,045,274

See accompanying notes to consolidated financial statements.

Interim Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited) For the six months ended June 30, 2018 and June 30, 2017 (Expressed in U.S. dollars)

			Warrant	Sto	ock options	Sh	ares to be	Со	ntributed	Acc	umulated other		
	S	hare Capital	Reserve		reserve		issued	S	surplus	comp	orehensive loss	Deficit	Total
Balance, January 1, 2017	\$	34,282,314	\$ 3,501,409	\$	993,211	\$	267,701	\$	59,940	\$	(530,000)	\$ (41,510,472)	\$ (2,935,897)
Issuance of common shares		12,874,132	-		-	(1,232,609)		-		-	-	11,641,523
Issuance of warrants and broker units		-	82,489		-		-		-		-	-	82,489
Exercise of warrants and options for common shares		212,928	(141,940)		(20,600)		-		-		-	-	50,388
Issuance of share-based compensation		59,117	-		293,147		-		-		-	-	352,264
Expiry of warrants and stock options		-	-		-		-		-		-	-	-
Net loss and comprehensive loss for the period		-	-		-		-		-		-	(4,004,717)	(4,004,717)
Shares to be issued		-	-		-		1,274,825		-		-	-	1,274,825
Balance at June 30, 2017	\$	47,428,491	\$ 3,441,958	\$	1,265,758	\$	309,917	\$	59,940	\$	(530,000)	\$ (45,515,189)	\$ 6,460,875

			Warrant	St	ock options	SI	hares to be	Co	ntributed	Acc	umulated other		
	S	hare Capital	Reserve		reserve		issued	S	surplus	comp	rehensive loss	Deficit	Total
Balance, January 1, 2018	\$	108,552,681	\$ 5,083,561	\$	1,087,640	\$; -	\$	59,940	\$	9,828	\$ (97,047,515)	\$ 17,746,135
Issuance of common shares (note 13)		17,033,148	-		-		-		-		-	-	17,033,148
Issuance of warrants and broker units (note 14)		-	426,367		-		-		-		-	-	426,367
Exercise of warrants and options for common shares (notes 14, 15)		12,416,403	(1,431,808)		-		-		-		-	-	10,984,595
Issuance of share-based compensation (note 15)		-	-		1,643,421		-		-		-	-	1,643,421
Expiry of warrants and stock options		-	-		(630,521))	-		-		-	630,521	_
Net loss and comprehensive loss for the period		-	-		-		-		-		(53,263)	11,375,256	11,321,993
Balance at June 30, 2018	\$	138,002,232	\$ 4,078,120	\$	2,100,540	\$; -	\$	59,940	\$	(43,435)	\$ (85,041,738)	\$ 59,155,659

See accompanying notes to consolidated financial statements.

Interim Consolidated Statement of Cash Flows (Unaudited) For the six month periods ended June 30, 2018 and 2017 (Expressed in U.S. dollars)

		F	or the six month	s ende	ed June 30,
			2018		2017
Cash provide by (used in):					
Operating activities:					
Net Gain (Loss)		\$	11,375,255	\$	(4,004,717)
Depreciation of property, plant and equipment	Note 8		703,795		133,303
Amortizaton of intangible assets			151,290		-
Loss on disposal of assets			5,000		294,200
Interest expense			915,575		857,432
Income taxes paid			(324,620)		-
Income tax expense			8,420		200,000
Bad debt expense			140,545		275,699
Share based compensation	Note 15		1,643,421		376,569
Professional fees paid with equity instruments			-		167,491
(Gain)/loss on fair value adjustment to warrants liability			(10,627,702)		(238,379)
(Gain)/loss on fair value adjustment to debt	Note 10		(10,198,949)		-
Gain on fair value of biological assets	Note 7		(692,165)		-
Reserve for obsolete inventory	Note 7		388,586		-
Impairment of finance lease receivable			-		54,844
Other non-cash transactions			(329,983)		(860,979)
Changes in working capital items					
Accounts receivable	Note 6		(33,718)		6,195
Other receivabales			(136,233)		150,000
Sales tax recoverable			(106,617)		(104,762)
Accounts payable and accrued liabilities	NI (7		(983,729)		1,383,941
Biological assets	Note 7		380,117		-
Inventory Cash used in operating activities	Note 7	\$	(825,258) (8,340,575)	\$	(1,209,444) (2,518,607)
NVESTING ACTITIVES					
Deposits on property, plant and equipment	Note 8		-		(10,000)
Purchase of property, plant and equipment	Note 8		(823,561)		(1,076,245)
Payment of deposits and retainers			(372,239)		(49,527)
Purchases of intangible assets			-		(1,527,915)
Payment of accrued transaction costs			(536,896)		-
Cash used in investment activities		\$	(1,732,696)	\$	(2,663,687)
	No. 40		04.000.004		4 057 050
Issuance of common shares	Note 13		21,669,001		1,857,250
Payment of share issuance costs	Note 13		(1,021,949)		-
Repayment of long-term debt			(183,265)		(19,110)
Interest paid			(697,000)		-
Repayment of related party loan		¢	-	¢	(500,000)
Cash provided by financing activities		\$	19,766,787	\$	1,338,140
ncrease/(Decrease) in cash during the period		\$	9,693,516	\$	(3,844,154
Cash, beginning of period			6,009,447		3,940,463
Cash, end of period		\$	15,702,963	\$	96,309
Interest paid during the period		\$	915,575	\$	-

See accompanying notes to these consolidated financial statements

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

1. Incorporation and operations

Golden Leaf Holdings Ltd. ("Golden Leaf" or the "Company") is a publicly traded corporation, incorporated in Canada, operating primarily in the Oregon, Nevada, and Canadian markets. The company's shares are listed on the CSE under the trading symbol "GLH", as well as the OTCQB under the trading symbol "GLDFF".

The Company is in the business of producing and distributing cannabis oil and flower products within the Oregon and Nevada adult-use regulated market as well as the Canadian medical market, primarily through its main operating subsidiaries, Greenpoint Oregon, Inc., Greenpoint Nevada, Inc., and CFA Retail, LLC, Medical Marijuana Group Corporation and Medical Marijuana Group Consulting Ltd.

2. Going concern

Golden Leaf has been incurring operating losses and cash flow deficits since its inception, as it attempts to create an infrastructure to capitalize on the opportunity for value creation that is emerging from the gradual relaxing of prohibitions of cannabis in the United States on the cannabis industry. The Company's revenues have not yet risen to levels materially capable of covering the costs related to the infrastructure investment (both capital and operating). As such, the Company has been depleting its invested capital as it simultaneously navigates regulatory evolution and uncertainty, awaits the imminent changes in other jurisdictions that will fuel market expansion, and continues to make necessary investments.

As of June 30, 2018, the Company's cash balances were \$15,702,963. On January 31, 2018 the Company received gross proceeds of C\$17,554,050 from a bought deal private placement transaction, in addition to significant warrant exercise activity which has further bolstered the Company's cash position.

Although the Company has been successful in raising funds to date, there can be no assurance that adequate or sufficient funding will be available in the future or available under terms acceptable to us or that the Company will be able to generate sufficient cash flow from operations.

These circumstances indicate the existence of material uncertainty that casts substantial doubt as to our ability to meet our business plan and our obligations as they come due, and accordingly the appropriateness of the use of the accounting principles applicable to a going concern. The accompanying consolidated financial statements have been prepared on a going concern basis that assumes we will be able to continue to realize our assets and discharge our liabilities in the normal course of business, and do not reflect the adjustments to assets and liabilities that would be necessary if we were unable to obtain adequate financing. Such adjustments could be material. If we are unable to raise funds and execute our business plan, we may not be able to continue as a going concern.

3. Statement of compliance

These interim condensed consolidated financial statements for the three and six-month periods ended June 30, 2018 have been prepared in accordance with IAS 34, 'Interim Financial Reporting' and in accordance with the accounting policies adopted in the Company's most recent annual financial statements for the year ended December 31, 2017. The interim condensed consolidated financial statements should be read in conjunction with the December 31, 2017 financial statements, which have been prepared in accordance with International Financial Reporting Standards ("IFRS").

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

4. Basis of presentation

Except where specified, the consolidated financial statements have been prepared in U.S. dollars, which is the Company's presentation currency, on a historical cost basis except for biological assets, certain financial assets, and financial liabilities measured at fair value. The accounting policies set out below have been applied to all accounting periods. Certain prior period amounts have been reclassified for consistency with current period presentation. These reclassifications had no effect on the reported results of operations.

5. Significant accounting policies

The accounting policies applied in these interim condensed consolidated financial statements are the same as those applied in the Company's Consolidated Financial Statements for the year ended December 31, 2017 with the exception of the following:

Changes in Accounting Policies – Financial Instruments

The Company adopted all of the requirements of IFRS 9 Financial Instruments ("IFRS 9") as of January 1, 2018. IFRS 9 replaces IAS 39 Financial Instruments: Recognition and Measurement ("IAS 39"). IFRS 9 utilizes a revised model for recognition and measurement of financial instruments and a single, forward-looking "expected loss" impairment model. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward in IFRS 9, so the Company's accounting policy with respect to financial liabilities is unchanged. As a result of the adoption of IFRS 9, management has changed its accounting policy for financial assets retrospectively, for assets that continued to be recognized at the date of initial application. The change did not impact the carrying value of any financial assets or financial liabilities on the transition date.

The following is the Company's new accounting policy for financial instruments under IFRS 9:

(i) Classification

The Company classifies its financial instruments in the following categories: at fair value through profit and loss ("FVTPL"), at fair value through other comprehensive income (loss) ("FVTOCI") or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company's business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or if the Company has opted to measure them at FVTPL.

The Company completed a detailed assessment of its financial assets and liabilities as at January 1, 2018. The following table shows the original classification under IAS 39 and the new classification under IFRS 9:

Financial asset / liabilities	Original classification IAS 39	New classification IFRS 9
Cash	Amortized cost	Amortized cost
Account receivable	Amortized cost	Amortized cost
Account payable and accrued liabilities	Amortized cost	Amortized cost
Interest payable	Amortized cost	Amortized cost
Long-term debt	Amortized cost	Amortized cost
Convertible debentures	FVTPL	FVTPL
Related party notes payable	Amortized cost	Amortized cost
Warrants liability	FVTPL	FVTPL
Derivative liability	FVTPL	FVTPL

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

5. Significant accounting policies (continued)

The Company did not restate prior periods as it recognized the effects of retrospective application to shareholders' equity at the beginning of the 2018 annual reporting period, which also includes the date of initial application. The adoption of IFRS 9 resulted in no impact to the opening accumulated deficit nor to the opening balance of accumulated comprehensive income on January 1, 2018.

(ii) Measurement

<u>Financial assets and liabilities at amortized cost</u>. Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment.

<u>Financial assets and liabilities at FVTPL</u>. Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the consolidated statements of net (loss) income. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the consolidated statements of net (loss) income in the period in which they arise.

(iii) Impairment of financial assets at amortized cost

The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the consolidated statements of net (loss) income, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized.

(iv) Derecognition

<u>Financial assets</u>. The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Gains and losses on derecognition are generally recognized in the consolidated statements of net (loss) income.

Changes in Accounting Policies – Revenue from Contracts with Customers

The company adopted all requirements of IFRS 15 Revenue from Contracts with Customers ("IFRS 15") as of January 1, 2018. IFRS 15 utilizes a methodical framework for entities to follow to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The change did not impact the cumulated revenue recognized or the related assets and liabilities on the transition date.

The company has assessed the impact from this new standard. Under IFRS 15, revenue from the sale of cannabis would be recognized at the point in time when control over goods has been transferred to the customer. The Company transfers control and satisfies its performance obligation upon delivery and acceptance by the customer, which is consistent with the Company's previous revenue recognition policy under IAS 18.

Based on the Company's assessment, the adoption of this new standard does not have a material impact on its consolidated financial statements.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

5. Significant accounting policies (continued)

New Accounting Policy – Biological Assets

On April 1, 2018, the Company adopted a production costs capitalization policy. A portion of production costs related to the transformation of biological assets from the point of recognition to the point of harvest are capitalized and included in the fair value measurement of biological assets. Previously, production costs were expensed as incurred. The adoption of this policy does not represent a change in an accounting policy under IAS 8, *Accounting Policies, Changes in Accounting Estimates and Errors,* as production costs related to cannabis cultivation and grow activities were previously immaterial to the Company's financial results.

6. Accounts receivable

	Jur	ie 30, 2018	Decen	nber 31, 2017
Accounts receivable	\$	343,755	\$	377,746
Allow ance for doubtful accounts		(72,836)		-
	\$	270,919	\$	377,746

7. Biological assets and inventory

The Company's biological assets consist of cannabis plants that are cultivated at the Company's own grow facilities. Biological assets are valued in accordance with IAS 41, and are presented at fair value less costs to sell up to the point of harvest, which becomes the basis for the cost of finished goods inventories after harvest. Since actively traded commodity market prices are not available for cannabis plants or dried product, the valuation of these biological assets is obtained using valuation techniques where the inputs are based upon unobservable market data (Level 3).

The valuation of biological assets is based on a market approach where fair value at the point of harvest is estimated based on the selling price less any costs to sell at harvest. For biological assets that are still growing, the fair value ascribed to them is a percentage of the fair value at point of harvest, based on where the plants are in their grow cycle. As at June 30, 2018, on average, the biological assets were 48% complete as to the next expected harvest date. There were no biological assets at June 30, 2017.

On April 1, 2018, the Company adopted a production costs capitalization policy. A portion of production costs related to the transformation of biological assets from the point of recognition to the point of harvest are capitalized and included in the fair value measurement of biological assets. Previously, production costs were expensed as incurred. The adoption of this policy does not represent a change in an accounting policy under IAS 8, *Accounting Policies, Changes in Accounting Estimates and Errors,* as production costs related to cannabis cultivation and grow activities were previously immaterial to the Company's financial results.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

7. Biological assets and inventory (continued)

In determining the fair value of biological assets, management is required to make several estimates with respect to significant unobservable inputs, including the expected yields for the cannabis plants, listed selling price of dry cannabis, the stage of plant growth at which point of harvest is determined, and costs to sell. Estimated yield per plant varies by strain and is obtained through historical growing results or grower estimate if historical results are not available. The Company used a range of 90.8 to 177.66 grams per plant in valuation of biological assets at June 30, 2018. The listed selling price of dry cannabis varies by strain and is obtained through listed selling prices or estimated selling prices if historical results are not available. The Company used a range of \$2.42 to \$4.19 per gram in valuation of biological assets at June 30, 2018. Increases in sales price and expected yield for the cannabis plants will increase the fair value of biological assets, and vice versa.

During the six-month periods ended June 30, 2018 and 2017 the Company recognized \$706,257 and \$0, respectively, of gain on the change in fair market value of biological assets reflecting the increased value relating to the growth and harvest of the flower from cannabis plants. This gain was calculated using a periodic change in value based on plant count and estimated value of the various products from the plants.

Inventory consists of cannabis flower, concentrated products such as oils and edibles, packaging, trim, and paraphernalia. During the six-month periods ended June 30, 2018 and 2017, \$168,954 and \$187,727 respectively, of depreciation was allocated to inventory and expensed as cost of sales. Any costs incurred to bring inventory to the condition and location of sale are included in cost. Inventory expensed to cost of sales for the six-month periods ended June 30, 2018 and 2017 was \$5,754,508 and \$3,368,899, respectively. The following provides a summary of the various costs incurred in key stages of production:

	Biolo	gical assets	Inventory
Raw materials	\$	-	\$ 451,767
Work-in-process		90,627	1,274,542
Finished goods		-	1,896,946
Balance, December 31, 2017	\$	90,627	\$ 3,623,255
Raw materials		-	1,116,132
Work-in-process		402,675	1,054,760
Finished goods		-	1,699,535
Balance, June 30, 2018	\$	402,675	\$ 4,059,927

During the six-month period ended June 30, 2018, the Company expensed \$196,456 of packaging materials to Inventory expenses to cost of sales which were destroyed due to obsolescence after the balance sheet date. The Company also recorded a general reserve for excess and obsolete inventory in the amount of \$192,100.

The Company's biological assets at June 30, 2018 is comprised of:

Balance, December 31, 2017	\$ 90,627
Gain on fair value of Biological assets	706,257
Increase in biological assets due to capitalized costs	117,743
Transfer to Finished goods	(511,952)
Balance, June 30, 2018	\$ 402,675

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

8. Property, plant and equipment

	Bui	ldings and			Prod	luction	L	easehold	Сс	omputer	Fu	rniture and				
	imp	rovements	La	and	equi	ipment	imp	provements	Eq	uipment		Fixtures	<u>\</u>	/ehicles		Total
Cost																
Balance, Dec 31, 2017	\$	867,351	\$29	0,404	\$1,8	35,863	\$	3,736,610	\$ 2	235,778	\$	938,496	\$	222,112	\$8	,126,614
Additions		115,915		-	1	33,787		483,207		83,886		19,424		-		836,219
Dispositions		-		-		-		-		-		(36,236)		-		(36,236)
Balance, June 30, 2018	\$	983,266	\$29	0,404	\$1,9	69,650	\$	4,219,817	\$;	319,664	\$	921,684	\$	222,112	\$8	,926,597
Accumulated Amortiza	tion															
Balance, Dec 31, 2017	\$	-	\$	-	\$ (6	09,494)	\$	(920,057)	\$(109,279)	\$	(423,093)	\$	(107,781)	\$(2	,169,704)
Expense		(97,796)		-	(1	80,929)		(295,345)		(27,402)		(95,117)		(24,864)		(721,453)
Dispositions		-		-		-		-		-		36,236		-		36,236
Balance, June 30, 2018	\$	(97,796)	\$	-	\$ (7	90,423)	\$	(1,215,402)	\$(136,681)	\$	(481,974)	\$	(132,645)	\$(2	,854,921)
Carrying amount																
Balance, Dec 31, 2017	\$	867,351	\$29	0,404	\$1,2	26,369	\$	2,816,553	\$	126,499	\$	515,403	\$	114,331	\$5	,956,910
Balance, June 30, 2018	\$	885,470	\$29	0,404	\$1,1	79,227	\$	3,004,415	\$	182,983	\$	439,710	\$	89,467	\$6	,071,676

Total depreciation expense for the six months ended June 30, 2018 and 2017, was \$721,726 and \$416,934, respectively. Of the total expense, \$168,954 and \$187,727 was allocated to inventory during the six months ended June 30, 2018 and 2017, respectively.

9. Intangible Assets

	Balance at January 1, 2018 Additions		Disposals / adjustments		Balance at June 30, 2018		
Cost		•					
License	\$	11,414,220	\$ -	\$	-	\$	11,414,220
Customer Relationships		1,512,896	-		-		1,512,896
Brands		13,300,000	-		-		13,300,000
Total	\$	26,227,116	\$ -	\$	-	\$	26,227,116
Accumulated Amortization							
License	\$	-	\$ -	\$	-	\$	-
Customer Relationships		-	(151,290)		-		(151,290)
Brands		-	-		-		-
Total	\$	-	\$ (151,290)	\$	-	\$	(151,290)
Net book value	\$	26,227,116	\$ (151,290)	\$	-	\$	26,075,826

10. Convertible debt and notes payable

	Jur	ne 30, 2018	December 31, 2017		
Current portion of convertible debentures carried at fair value	\$	-	\$	271,245	
Mortgage note payable		313,816		389,916	
Convertible debentures carried at fair value		12,016,126		30,360,225	
Carrying amount of convertible notes at end of period	\$	12,329,942	\$	31,021,386	

The Company has elected to account for the convertible debentures at fair value through profit and loss on initial recognition and as of the date of extinguishment for its convertible debentures. A gain of \$9,970,603 has been recorded through change in fair value of liabilities on the Consolidated Statement of Operations and Comprehensive Gain (Loss) for the six-month period ended June 30, 2018.

For the year ended December 31, 2017, \$18.14 million debentures were converted. For the six-month period ended June 30, 2018, \$6.69 million debentures have been converted.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

11. Long-term debt

	Jur	e 30, 2018	December 31, 2017		
Long term debt	\$	104,826	\$	211,991	
Less: current portion		(40,371)		(131,610)	
Carrying amount of long-term debt	\$	64,455	\$	80,381	

Long term debt consists of vehicle loans, one of which was paid off in entirety in Q2 2018. Vehicle loans of \$159,599 are secured by the Company's vehicles, due in June 2021 and repayable in monthly blended installments of \$2,155.

12. Warrants liability

	Units	Amount
Balance, December 31, 2017	117,765,944 \$	14,300,616
Warrants issued	38,980,000 \$	3,810,975
Warrants exercised	(18,481,615)	(3,077,592)
Change in fair market value		(10,627,702)
Balance, June 30, 2018	138,264,329 \$	4,406,297

In conjunction with the Company's bought deal unit financing which closed in January 2018, the Company issued 38,980,000 warrants exercisable for 24 months from the date of closing at a price of C\$0.55.

Per IFRS 9, certain warrants meet the definition of a derivative and must be measured at fair value at each reporting date. The warrants were valued at \$4,406,297 at June 30, 2018 and \$14,300,616 at December 31, 2017. For the six months ended June 30, 2018, a gain of \$10,627,702 was recorded in the statement of operations due to significant changes in the market price of the common shares. The Black-Scholes option pricing model was used at the date of measurement with the following assumptions:

	June 30, 2018	December, 31 2017
Expected life	1.3 - 1.7 years	1.3 - 1.9 years
Risk-free interest rate	1.79%	0.84%
Dividend yield	0.00%	0.00%
Foreign exchange rate	0.7609	0.7701
Expected volatility	70.00%	70.00%

Volatility was calculated by using the historical volatility of other companies that the Company considers comparable that have trading and volatility history prior to the Company becoming public. The expected life in years represents the period that the warrants granted are expected to be outstanding. The risk-free rate is based on zero coupon Canada government bonds with a remaining term equal to the expected life of the options.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

13. Share capital

Share capital consists of one class of fully paid Ordinary Shares, with no par value. The Company is authorized to issue an unlimited number of Ordinary Shares. All shares are equally eligible to receive dividends and repayment of capital and represent one vote at the Company's shareholders' meetings.

The following table reflects the continuity of share capital from December 31, 2017 to June 30, 2018:

	Number of Shares	 Amount
Balance, December 31, 2017	477,000,336	\$ 108,552,681
Shares issued - conversion of debentures (i)	31,395,482	7,588,887
Shares issued - w arrant exercises (ii)	30,098,819	12,416,403
Shares issued - private placement financing (iii)	38,980,000	9,028,092
Shares issued - payment of accrued commissions and transaction costs (iv)	1,622,692	416,169
Balance, June 30, 2018	579,097,329	\$ 138,002,232

- (i) During the first six months of 2018, 31,395,482 shares were issued in respect of conversion of convertible debentures.
- (ii) The Company issued 30,098,819 shares upon exercise of warrants and compensation options.
- (iii) During the first six months of 2018, 38,980,000 shares were issued in conjunction with the bought deal private placement unit offering resulting in gross proceeds of C\$17,541,000; C\$4,702,743 of these proceeds were allocated to warrant liabilities (Note 12). The Company paid share issuance costs of C\$1,263,779 for this transaction.
- (iv) The Company issued 1,622,692 shares as payment for accrued commissions payable and transaction costs.

14. Warrant reserve

	Number of warrants issued	Exercise price	Am	ount
Balance, December 31, 2017	29,274,531		\$	5,083,561
Warrants issued (i)	2,278,800	CDN \$0.45	\$	426,367
Warrants issued (ii)	5,425,995	CDN \$0.37		-
Exercise of compensation options (iii)	(10,851,990)			(1,402,433)
Exercise of warrants (iv)	(796,167)			(29,375)
Balance, June 30, 2018	25,331,169		\$	4,078,120

- (i) The Company issued 2,278,800 warrants as compensation options at C\$0.45 as part of the bought deal private placement offering.
- (ii) The Company issued 5,425,995 warrants at C\$0.37 upon exercise of compensation options. The value of these warrants has been previously recorded upon initial recognition of compensation options.
- (iii) During the first quarter 2018, 10,851,990 compensation options were exercised.
- (iv) During the first quarter 2018, 796,167 warrants were exercised.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

14. Warrant reserve (continued)

The warrants were valued based on the fair value of services received unless the fair value of services received cannot be reliably measured, in which case the warrants are valued at fair value based on the Black-Scholes option pricing model at the date of measurement with the following assumptions:

	June 30, 2018	December, 31 2017
Expected life	1.3 - 1.7 years	1.3 - 1.9 years
Risk-free interest rate	1.79%	0.84%
Dividend yield	0.00%	0.00%
Foreign exchange rate	0.7609	0.7701
Expected volatility	70.00%	70.00%

Volatility was calculated by using the historical volatility of other companies that the Company considers comparable that have trading and volatility history prior to the Company becoming public. The expected life in years represents the period of time that the options granted are expected to be outstanding. The risk-free rate is based on zero coupon Canada government bonds with a remaining term equal to the expected life of the options.

15. Stock option plan

On January 1, 2015, the Company's Board of Directors approved a Directors, Management, Employees and Consultants Stock Option Plan to provide an incentive to its directors, executives and employees.

In accordance with terms of the employee share option plan, the exercise price of the granted options shall be determined at the time the option is granted provided that such price shall be not less than the market price of the Ordinary Shares. The total number of shares to be issued under the plan is not to exceed 10% of the total issued and outstanding shares. The options vest evenly over 3 years and have an expiry period of no more than 10 years from the grant date.

Total number of options at December 31, 2017	22,057,223	
Options granted at \$0.39 Canadian dollars	23,550,000	
Options granted at \$0.26 Canadian dollars	4,250,000	
Options granted at \$0.22 Canadian dollars	13,750,000	
Options expired	(6,970,835	
Total number of options at June 30, 2018	56,636,388	
Number of exercisable options issued in Canadian dollars	25,751,635	
Number of exercisable options issued in U.S. dollars	1,160,046	
Weighted average exercise price of options at June 30, 2018 in USD	\$ 0.28	

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

15. Stock option plan (continued)

The options were valued based on the Black-Scholes option pricing model at the date of measurement with the following assumptions:

	June 30, 2018	December 31, 2017
Expected life	3 years	3 years
Risk-free interest rate	1.66%	0.00%- 1.59%
Dividend yield	0.00%	0.00%
Expected volatility	70.00%	70.00%
Expected forfeiture rate	0.00%	0.00%

During the six months ended June 30, 2018 and 2017, \$1,643,421 and \$376,570, respectively, was included in stock compensation expense in the consolidated statement of operations.

On January 24, 2018, the Company issued 23,550,000 stock options to employees and consultants with an exercise price of C\$0.39.

16. Commitments

The Company and its subsidiaries have entered into operating lease agreements for the Company's dispensaries, corporate offices, wholesale warehouses, and grow facilities. Future lease payments amount to \$7,607,575:

2018	\$ 766,698
2019	1,857,155
2020	1,628,024
2021	1,317,154
2022	797,157
Thereafter	1,241,387
	\$ 7,607,575

17. Related party transactions

Key management of the Company are its Board of Directors and certain members of executive management. Key management personnel remuneration for the three months ended June 30, 2018 includes the following expenses:

	2018	2017
Salaries, commissions, bonuses and benefits	\$ 539,884	\$ 315,747
Stock Compensation, including warrants and shares, for officers and directors	932,245	91,088
	\$ 1,472,129	\$ 406,835

The Company leases both its corporate headquarters in Portland and its grow facility outside of Portland, which is currently under construction, from CPP OR LLC ("CPP"), of which Gary Zipfel, Director, is the sole member. To support the Company, CPP entered into a rent abatement agreement with the Company for the entirety of 2018 for its corporate headquarters and Oregon cultivation facility. Additional rent in the amount of \$23,536 payable to CPP began in May 2018 to support the Company's corporate headquarters and production build out costs and is included in its commitments schedule. Rent payment on the corporate headquarters and cultivation facility will resume in 2019.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

18. Capital management

The Company defines capital that it manages as its shareholders' equity, long-term debt, convertible debt, and warrant liability. The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to pursue the development of its business and to maintain a flexible capital structure which optimizes the costs of capital at an acceptable risk.

The Company manages the capital structure and adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may issue shares, acquire debt, or acquire or dispose of assets.

To facilitate the management of its capital requirements, the Company prepares annual expenditure budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. These budgets are approved by the Company's Board of Directors.

19. Legal Matters

The Company and its wholly-owned subsidiary Greenpoint Real Estate, LLC, an Oregon limited liability company (collectively, the "Defendants"), were sued in the Circuit Court of the State of Oregon in Lane County on November 7, 2017 by the plaintiff, 3590 West 3rd Owner, LLC, an Oregon limited liability company ("Plaintiff"). The claims made by Plaintiff arise out of a lease between the parties and are breach of contract, foreclosure of landlord's lien and foreclosure of security interest. The amount of damages claimed are \$3,210,327, plus interest and certain other fees and costs. The Defendants deny all of the claims made and are preparing an Answer to file in response to the Plaintiff's Complaint against the Defendant's. The parties participated in a judicial settlement conference on March 14, 2018 in Portland, Oregon, for the purpose of attempting to reach a mutually agreeable settlement to resolve this matter. This attempt to settle was unsuccessful and Plaintiff filed an Amended Complaint on April 17, 2018. The Company filed an Amended Answer on May 1, 2018. The Company assesses the likelihood of a potential lawsuit as neither remote nor probable, and therefore has not recorded a provision for this loss at June 30, 2018.

20. Financial instruments and risk management

The Company, as part of its operations, carries several financial instruments. It is management's opinion that the Company is not exposed to significant interest, currency, credit, liquidity or other price risks arising from these financial instruments except as otherwise disclosed.

(a) Fair value

The carrying amounts of cash, accounts receivable, accounts payable, and accrued liabilities approximate their fair values because of the short-term maturities of these financial instruments.

The carrying value of long-term debt approximates fair value upon initial recognition. At June 30, 2018, its carrying value approximates fair value based on current market rates for similar instruments.

The following classifies financial assets and liabilities that are recognized on the balance sheet at fair value in a hierarchy that is based on significance of the inputs used in making the measurements. The levels in the hierarchy are as follows:

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

20. Financial instruments and risk management (continued)

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 – Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 – Inputs for the asset or liability that are not based on observable market data.

	Category	Le	vel 1	Le	vel 2	Level 3	Total
June 30, 2018			\$		\$	\$	\$
Financial Assets							
Available for sale purchase option	FVTPL	\$	-	\$	-	\$ -	\$ -
Financial Liabilities							
Warrant liability	FVTPL		-		-	4,406,297	4,406,297
Convertible debentures	FVTPL		-		-	12,016,126	12,016,126
	Category	Le	Level 1		vel 2	Level 3	Total
		December 31, 2017 \$					
December 31, 2017			\$		\$	\$	\$
,			\$		\$	\$	 \$
December 31, 2017 Financial Assets Available for sale purchase option	FVTPL	\$	\$ -	\$	\$ -	\$ \$ -	\$ \$
Financial Assets Available for sale purchase option	FVTPL	\$	<u>\$</u>	\$	•	\$ \$	\$ \$ -
Financial Assets	FVTPL FVTPL	\$	\$	\$	•	\$ \$ - 14,300,616	\$ \$ - 14,300,616

The Company's finance team performs valuations of financial items for financial reporting, including Level 3 fair values, in consultation with third party valuation specialists for complex valuations. Valuation techniques are selected based on the characteristics of each instrument, with the overall objective of maximizing the use of market-based information.

The convertible debentures were valued using a binominal option pricing model to estimate the value of the combined convertible instrument. The most significant assumption used in this valuation is the expected volatility of the Company's shares which has been estimated at 70%.

Refer to Note 12 for further information on valuation of warrant liability.

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

(b) Credit risk

The carrying amounts of cash and accounts receivable on the consolidated statement of financial position represent the Company's maximum credit exposure at June 30, 2018.

The Company's principal financial assets are cash held at a highly rated financial institution and accounts receivable, which are subject to credit risk.

The Company's credit risk is primarily attributable to its accounts receivable. The amounts disclosed in the consolidated statement of financial position are net of allowance for doubtful accounts, estimated by the management of the Company based on its assessment of the current economic environment.

The Company does not have significant exposure to any individual customer and has estimated bad debts of \$72,836 at June 30, 2018 and \$0 at December 31, 2017.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

20. Financial instruments and risk management (continued)

(c) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not subject to any interest rate volatility as its long-term debt instruments and convertible notes are carried at a fixed interest rate throughout their term.

(d) Liquidity risk

The Company's objective is to have sufficient liquidity to meet its liabilities when due. The Company monitors its cash balances and cash flows generated from operations to meet its requirements. To ensure the Company has sufficient liquidity to meet its obligations, the Company intends to issue common shares and debt in the future. The following table summarizes the Company's contractual maturity for its financial liabilities, including both principal and interest payments:

	Carrying amount		ontractual ash flows	Under 1 year			1-3 years	3-5	years	More than 5 years		
As at June 30, 2018												
Trade and other payables	\$ 1,128,704	\$	1,128,704	\$	1,128,704	\$	-	\$	-	\$	-	
Loans and other borrow ings	418,642		418,642		313,816		64,455		-		-	
Convertible debt	12,016,126		12,016,126		-		12,016,126		-		-	
Total	\$ 13,563,472	\$	13,563,472	\$	1,442,520	\$	12,080,581	\$	-	\$	-	

(e) Foreign exchange risk

Foreign currency exchange risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currencies. The Company has financial assets and liabilities denominated in Canadian dollars. The Company does not hedge its exposure to fluctuations in foreign exchange rates.

The following is an analysis of U.S. dollar equivalent of financial assets and liabilities that are denominated in Canadian dollars at June 30, 2018:

Financial Assets	
Cash	\$ 6,861,127
Trade and other receivables	-
	\$ 6,861,127
Financial Liabilities	
Trade and other payables	\$ 249,226
Loans and other borrow ings	313,895
Convertible debt	12,016,126
	\$ 12,579,247

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

21. Segmented Information

The Company defines its major operating segments as Oregon wholesale, Oregon retail, Nevada wholesale, Canada cultivation and Canada Consulting. Due to the jurisdictional cannabis compliance issues ever-present in the industry, each state operation is by nature an operational segment. The Oregon wholesale and retail operations share supply chain components and cannot be discretely separated beyond gross margin; however, they have disparate revenue and margin metrics and thus will be presented as such. The Nevada wholesale operations are geographically and jurisdictionally distinct and are reviewed based on gross margin performance. The Canadian companies, although under common management, are different business models and thus are reviewed by management independently based on revenues and gross margin.

Key decision makers primarily review revenue, cost of sales expense and gross margin as the primary indicators of segment performance. The Oregon wholesale operation has historically been the major focus on the Company's management activities, however the addition of Retail and Nevada has further broadened the scope of management's activities. As these management activities continue to coalesce, the segment information will expand based on managements agreed upon allocation of costs beyond gross margin.

For the three months ended		Oregon		Oregon		Nevada		Canada		Canada		Other		
June 30, 2018		Retail	W	holesale	w	holesale	C	Cultivation	С	onsulting	u	nallocated	Co	onsolidated
Product sales	\$	2,638,272	\$	481,375	\$	363,764	\$	-	\$	188,751	\$	-	\$	3,672,162
Consulting revenue		-		-		-		-		9,474		-		9,474
Total Revenue	\$	2,638,272	\$	481,375	\$	363,764	\$	-	\$	198,225	\$	-	\$	3,681,636
Inventory expensed to cost of sales		2,074,834		862,493		92,468		-		-		-		3,029,795
Production costs		-		111,277		2,476		-		-		-		113,753
Gross margin before the undernoted	\$	563,438	\$	(492,395)	\$	268,820	\$	-	\$	198,225	\$	-	\$	538,088
Fair value changes in biological assets included														
in inventory sold and other inventory charges		-		-		10,518		-		-		-		10,518
Gain on changes in fair value of biological assets		-		-		(25,469)		(372,799)		-		-		(398,268)
Gross profit	\$	563,438	\$	(492,395)	\$	283,771	\$	372,799	\$	198,225	\$	-	\$	925,838
Assets	\$4	40,809,244	\$	9,453,937	\$	4,258,841	\$	11,538,283	\$	4,329,899	\$	16,354,751	\$	86,744,955
Liabilities	\$	341,973	\$	(619,428)	\$	(4,345)	\$	203,765	\$	123,713	\$	27,543,619	\$	27,589,297

22. Subsequent events

Subsequent to the balance sheet date, \$392,000 of debentures have been converted into 1,866,665 shares.

On August 2, 2018, the Company received its city regulatory license to operate its extraction facility in the city of Portland, Oregon. After a long and arduous licensing and permitting process, the required modifications to the extraction facility were completed, and the facility was approved to extract cannabis oil. Immediately upon receipt of the city's licence, the Company's production team began operating the extraction equipment.

On August 10, 2018, the Company signed a definitive agreement to acquire the assets of Tahoe Hydroponics Company and 11T Corp (collectively, "Tahoe"). Under the terms of the agreement, the Company will acquire all Nevada and California assets of Tahoe for a total consideration of approximately C\$52.4M. Tahoe shareholders will receive approximately C\$11.1M in cash plus approximately 202,000,000 shares of the Company's stock, based on a 20-day VWAP of C\$0.2050 for the period ended August 10, 2018. This equates to a value of C\$41.3M and is approximately 25.8% of the combined company. The share consideration will be released over 18 months, with a portion subject to an earnout. The agreement remains subject to certain customary conditions, including the applicable regulatory approvals, as well as the approval of the Nevada Department of Revenue.

Notes to the Interim Condensed Consolidated Financial Statements (Expressed in U.S. dollars, unless otherwise stated) For the three and six months ended June 30, 2018

On August 16, 2018, the Company signed a definitive agreement to acquire a combined cultivation, production and retail license in California. Under the terms of the Contingent Asset Purchase Agreement, upon closing Golden Leaf will acquire the multi-use "Sweet 16" license, as well as certain assets of the seller including cash, inventory, equipment and contractual rights for US\$7,146,582, consisting of US\$1.25M in cash at closing and US\$500,000 of GLH stock based on the VWAP for the 30-days immediately preceding the closing date. The balance of the purchase price of US\$5,396,582 is cash earn-out consideration to be paid over time based upon the net wholesale and net retail revenues generated from the Company's San Jose facility. The lease is at market rates and the initial term of the lease agreement is for a period of five years. Closing of the transaction is subject to customary contingencies, including licensing approvals.